• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Sol-Gel Technologies Ltd.

    1/26/23 6:07:18 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLGL alert in real time by email
    SC 13G 1 zk2329058.htm SC 13G zk1617981.htm

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
    (Amendment No. __)
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d)
    AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
     
    Under the Securities Exchange Act of 1934
     
    Sol-Gel Technologies Ltd.
    (Name of Issuer)
     
    Ordinary Shares
    (Title of Class of Securities)
     
     
    M8694L103
     
    (CUSIP Number)
     
    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)
     
    Check the following box to designate the rule pursuant to which the Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☒ Rule 13d-1(c)
     
    ☐ Rule 13d-1(d)
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     
    CUSIP NO.  M8694L103
     
    1.
    Name of Reporting Person
     
    Migdal Insurance & Financial Holdings Ltd
    2.
    Check the Appropriate Box if a Member of a Group
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     
     
    4.
    Place of Organization
     
    Israel
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5.
    Sole Voting Power
     
     
    6.
    Shared Voting Power
     
    1,230,636 Ordinary Shares *
    7.
    Sole Dispositive Power
     
     
    8.
    Shared Dispositive Power
     
    1,230,636 Ordinary Shares *
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,230,636 Ordinary Shares *
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.32%**
    12.
    Type of Reporting Person :               
     
    HC

    *See Item 4.
    ** Based on 23,119,068 ordinary shares issued and outstanding as of December 31, 2022 (according to publicly available information provided by the issuer).

    Page 2 of 5 pages


    Item 1.
     
    (a)
    Name of Issuer:
     
    Sol-Gel Technologies Ltd.
     
    (b)
    Address of Issuer’s Principal Executive Offices:
     
    Golda Meir 7, Ness Ziona 7403650
     
    Item 2.
     
    (a)-(c)     Name of Person Filing, address and citizenship:

    The foregoing entity is referred to as the “Reporting Person” in this Statement:
     
    Migdal Insurance & Financial Holdings Ltd., an Israeli public company, with a principal business address at  4 Efal Street; P.O. Box 3063; Petach Tikva 49512, Israel.
     
    (d)
    Title of Class of Securities:
     

    Ordinary Shares, NIS 0.01 par value per share (the “Ordinary Shares”)
     
    (e)
    CUSIP Number:
     

    M8694L103
     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     

    Not Applicable.
     
    Item 4.
    Ownership
     
    Of the 1,230,636 Ordinary Shares reported in this Statement as beneficially owned by the Reporting Person (i) 1,230,636 Ordinary Shares are held for members of the public through, among others, provident funds, mutual funds, pension funds and insurance policies, which are managed by direct and indirect subsidiaries of Reporting Person, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, and (ii)  - Ordinary Shares are held by companies for the management of funds for joint investments in trusteeship, each of which operates under independent management and makes independent voting and investment decisions, and (iii) - are beneficially held for their own account (Nostro account). Consequently, this Statement shall not be construed as an admission by the Reporting Person that it is the beneficial owner of 1,230,636 Ordinary Shares reported in this Statement except as set forth above, see items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which are incorporated herein.
     
    Item 5.
    Ownership of Five Percent or Less of a Class
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
     

    Not Applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
     

    See Exhibit below.
     
    Item 8.
    Identification and Classification of Members of the Group
     

    Not Applicable.
     
    Item 9. 
    Notice of Dissolution of Group
     

    Not Applicable.
     
    Page 3 of 5 pages

     
    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
    Exhibit to Item 7
     
    The subsidiaries of reporting person may make independent voting and/or investment decisions for client accounts include:
     
    Subsidiary Name
    Type of Subsidiary
    Migdal Insurance Company ltd.
    FI
    Migdal Makefet Pension and Provident Funds ltd.
    FI
    Yozma Pension Fund for Self Employed Ltd.
    FI
    Migdal Mutual Funds Ltd
    FI

    [SIGNATURE PAGE TO FOLLOW]
     
    Page 4 of 5 pages

     
    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    January 24, 2023
     
     
    MIGDAL INSURANCE AND FINANCIAL HOLDINGS LTD.
     
    BY: /s/ Tal Cohen
    authorized signatory of MIGDAL INSURANCE AND FINANCIAL HOLDINGS LTD.

    Page 5 of 5 pages

            
    Get the next $SLGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLGL

    DatePrice TargetRatingAnalyst
    8/19/2024$6.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/21/2022$5.50Hold
    Jefferies
    11/15/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    11/12/2021$23.00 → $21.00Strong Buy
    Raymond James
    7/28/2021$20.00 → $21.00Buy
    HC Wainwright & Co.
    7/12/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

      Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September

      11/15/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel's cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update. Alon Seri-Levy, PhD, Chief Executive Officer of Sol-Gel, stated, "We are very pleased with the continu

      11/10/22 4:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

      NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development. In this position, Mr. Glezin will be responsible for identifying new in-licensing business opportunities as well as potential commercial partners for the Company's approved products in ex-US territories. "We are very pleased to have Michael join the Company as we expand our business development efforts," stated Alon Seri-Levy,

      10/3/22 8:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sol-Gel Announces Reverse Share Split

      NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the "Company") (NASDAQ:SLGL), a clinical-stage dermatology company, today announced a reverse share split (the "Reverse Split") of the Company's issued and outstanding ordinary shares, par value NIS 0.1 per share (the "Ordinary Shares"), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share. The Company obtained shareholders' approval for the Reverse Split at a ratio of between 2:1 and 10:1 at a special meeting of shareholders, which took place on April 1, 2025. The Company's board of directors then approved the Reverse Split ratio of 10-for-1 on Ap

      5/1/25 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

      Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL

      4/17/25 8:40:29 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

      NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC's ("Nasdaq") minimum bid price rule. On November 19, 2024, the Company received a letter from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has d

      11/20/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TWYNEO issued to SOL-GEL TECHNOLOGIES LTD

      Submission status for SOL-GEL TECHNOLOGIES LTD's drug TWYNEO (ORIG-1) with active ingredient TRETINOIN;BENZOYL PEROXIDE has changed to 'Approval' on 07/26/2021. Application Category: NDA, Application Number: 214902, Application Classification: Type 4 - New Combination

      7/27/21 10:39:03 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

      SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      11/14/24 4:37:49 PM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

      SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      11/14/24 6:17:23 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Sol-Gel Technologies Ltd. (Amendment)

      SC 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      4/8/24 9:28:09 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    SEC Filings

    See more
    • SEC Form EFFECT filed by Sol-Gel Technologies Ltd.

      EFFECT - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/9/25 12:15:15 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Sol-Gel Technologies Ltd.

      424B3 - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/8/25 10:24:35 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 6-K/A filed by Sol-Gel Technologies Ltd.

      6-K/A - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/8/25 9:38:47 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Financials

    Live finance-specific insights

    See more
    • Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

      An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved lar

      3/13/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidate Sol-Gel has cash runway into the second half of 2025 NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3

      5/12/23 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

      Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase 3 study of SGT-610 is expected to initiate in the second half of 2023, with results expected by the end of 2025The base of recurrent TWYNEO® prescribers was 82% in Q4 2022, while the EPSOLAY® recurrent prescriber base has grown to 64% during the same periodFollowing recent financing, Sol-Gel's cash runway expected to extend into the second half of 2025 NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company wi

      3/10/23 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sol-Gel downgraded by Raymond James with a new price target

      Raymond James downgraded Sol-Gel from Strong Buy to Outperform and set a new price target of $4.00 from $6.00 previously

      8/19/24 6:57:49 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Sol-Gel with a new price target

      Jefferies resumed coverage of Sol-Gel with a rating of Hold and set a new price target of $5.50

      10/21/22 7:42:15 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sol-Gel Technologies with a new price target

      HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $20.00 from $21.00 previously

      11/15/21 1:18:47 PM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care